The combination of PARP inhibitor and APE1 inhibitor may be a candidate treatment for malignant hematological tumors, such as myelodysplastic syndromes/chronic myelomonocytic leukemia and acute myeloid leukemia. The gene discussed is APEX1; the disease is acute myeloid leukemia.